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ABSTRACT
Purpose. Many ionizable drugs are developed and marketed as salt forms. However,
there are no clear US regulatory guidelines on drug strength labeling for salts. The
strengths of some drugs are expressed as salts and some as free acids/bases. This study
surveyed the top 200 US drugs to assess the common practice in industry.
Methods. The top 200 drugs prescribed in US were included in this survey. The drugs
containing API salts were selected for analysis. Generic or combination products with
redundant API salts were excluded. The package insert of each selected drug was
reviewed, and the information on the drug strength expression was extracted and
categorized.
Results. Out of the top 200 drugs, 59 unique API salts were identified. The drug
strengths were expressed as salts for 32 drugs (54%) and as free acids/bases for 27 drugs
(46%).
Conclusion. The survey results revealed the inconsistent practice among the industry
regarding the drug strength expression for salts. Non-harmonized labeling practice can
lead to confusions, potential calculation/dosing errors, and complications in labeling new
products. The authors recommend the FDA and industry to standardize the labeling
format for salts and preferably express the drug strengths based on the free acid/base
forms.
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INTRODUCTION
Many drug molecules are weak acids or bases, and they can form stable salts with
the suitable counter ions [1-2]. For various reasons, the salt forms are often chosen as the
API (active pharmaceutical ingredient) forms for the development and commercialization
of the drug products [1-2]. Based on a recent study, 51.4% of the 1356 drugs in the US
Orange Book Database are formulated with the salt forms [3].
Currently, the US labeling requirements for drug products do NOT specify how
the drug strengths are expressed for salt forms, as evidenced by the relevant sections from
the Code of Federal Regulations (CFR) and United States Pharmacopoeia (USP) below.
Excerpts from CFR [4]
(a)(2) Drug names, dosage form, route of administration, and
controlled substance symbol. The proprietary name and the established
name of the drug, if any, as defined in section 502(e)(3) of the Federal
Food, Drug, and Cosmetic Act (the act) or, for biological products, the
proper name (as defined in §600.3 of this chapter) including any
appropriate descriptors. This information must be followed by the
drug's dosage form and route of administration.
(a)(8) Dosage forms and strengths. A concise summary of the
information required under paragraph (c)(4) of this section, with any
appropriate subheadings (e.g., tablets, capsules, injectable, suspension),
including the strength or potency of the dosage form in metric system
(e.g., 10-milligram tablets) and whether the product is scored.
(c)(4)3 Dosage forms and strengths. This section must contain
information on the available dosage forms to which the labeling applies
and for which the manufacturer or distributor is responsible, including:
(i) The strength or potency of the dosage form in metric system (e.g.,
10 milligram tablets), and, if the apothecary system is used, a statement
of the strength in parentheses after the metric designation; and
(ii) A description of the identifying characteristics of the dosage forms,
including shape, color, coating, scoring, and imprinting, when
applicable. The National Drug Code number(s) for the drug product
must not be included in this section.

Excerpt from USP [5]
10.40.10 Amount of Ingredient Per Dosage Unit
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The strength of a drug product is expressed on the container label in
terms of micrograms or milligrams or grams or percentage on the
therapeutically active moiety or drug substance, whichever form is used
in the title, unless otherwise indicated in an individual monograph.
Both the active moiety and drug substance names and their equivalent
amounts are then provided in the labeling.

As a result, the strengths of some drugs are expressed as the salt forms and some
as the free bases/acids. In other words, it is not possible for anyone to accurately interpret
the strength of a salt drug simply based on the drug product title and the strength. To
obtain such information, one has to read the “Description” section of the FDA-approved
drug labeling which is also known as the “package insert” and will be referred as such
throughout the rest of this article. In the Description section, the manufacturer typically
provides some clarification on the strength expression of the salt. Alternatively, this
information can be searched for in the Orange Book [6] or the Drugs@FDA database [7].
However, these publications do not accompany the drug products, and most users are not
aware of this feature.
In 2006, FDA amended its regulations governing the content and format of the
package insert [8]. The changes were intended to make it easier for the health care
practitioners to access, read, and use the prescribing information. However, the strength
expression issue mentioned above was not addressed. To make matters worse, the
Description section was moved from the beginning of the document to the middle,
making it more difficult for an average user to obtain the information needed to interpret
the drug strengths correctly.
Non-harmonized labeling practice can lead to unnecessary confusion and
mistakes among pharmaceutical scientists and health care practitioners. This study was
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initiated in order to survey the current practice in pharmaceutical industry regarding the
strength expression for drugs which are marketed in their salt forms.

METHODS
This survey included the top 200 drugs in the US market based on the number of
prescriptions dispensed in 2010 [9]. The package inserts of all 200 drugs were obtained
from DailyMed [10] for analysis. The drugs which did not contain API salt forms were
first eliminated. Potassium chloride products, quaternary ammonium salts, and proteins
were also excluded. The remaining drugs were then sorted to remove duplication. Multisource generic products containing the same API salt were counted as one entry; only the
highest ranking product was included in the data table. Combination drug products were
included if they contain at least one API salt which was not present as a single drug
product in the top 200 list. For example, hydrocodone/APAP was included, because
hydrocodone (bitartrate salt) was not available as a single drug product. Amlodipine
besylate/benazepril, on the other hand, was not included, because each of the two API
salts was available as a single drug product in the top 200 list. Hydrocodone bitartrate and
codeine phosphate were present in several different combination products, and only the
highest ranking product for each drug was included in the data table.
Once the non-salt and duplicate drugs were eliminated, the remaining drugs were
categorized into two groups: salts of weak acids and salts of weak bases. The Description
section of the package insert of each drug was carefully reviewed to identify whether the
strength of drug was expressed as the salt or free acid/base.
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RESULTS
The survey results are summarized in Figure 1. Out of the top 200 drugs
prescribed in 2010, 59 unique API salts were identified. Thirteen of the 59 drugs were
salts of acids; the drug strengths were expressed as the free acids for 7 drugs and as the
salts for 6 drugs. Forty-six drugs of the 59 drugs were salts of bases; the drug strengths
were expressed as the free bases for 20 drugs and as the salts for 26 drugs. The data on
the 59 individual drugs are presented in Tables 1 and 2 for acidic and basic drugs,
respectively. Overall, 54% products were labeled based on the salt forms and 46% based
on free acid/base forms.
In addition to the percent distributions, three noteworthy observations are
included below.
Amlodipine besylate/benazepril hydrochloride was a combination capsule product
(rank 136). The capsule strengths were expressed as the free base for amlodipine besylate
but as the salt for benazepril hydrochloride [10].
In the package insert of rosuvastatin calcium tablet (rank 16), it was not explained
whether the tablet strengths were expressed as the salt or the free acid [10]. Additional
information was obtained from the Drugs@FDA database [7], which verified that the
tablet strengths were expressed as the salt.
An error was noted in TEVA’s package insert of benazepril hydrochloride (rank
174), a generic product of Lotensin® from Novartis. The excerpts from the two package
inserts are shown below for comparison [10]. The term “hydrochloride” was apparently
omitted by mistake in TEVA’s document, which could be misleading for product strength
interpretation.
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Excerpt from TEVA’s Package Insert:
Benazepril hydrochloride is supplied as tablets containing 5 mg, 10 mg, 20 mg,
and 40 mg of benazepril for oral administration.

Excerpt from Novartis’s Package Insert:
Lotensin is supplied as tablets containing 5 mg, 10 mg, 20 mg and 40 mg of
benazepril hydrochloride for oral administration.

DISCUSSION
The molecular formula of a salt is different from that of the free acid/base due to
the presence of the counter ion. In some cases, the counter ion can account for a
significant fraction of the total formula weight. For example, escitalopram is marketed as
the oxalate salt [10]. The MW of escitalopram (free base) is 324, and the MW of
escitalopram oxalate is 414. The counter ion in this case is 21.7% of the salt. Fentanyl
citrate (not in top 200 list) represents an extreme case, where the citrate ion accounts for
36.3% of the total salt weight.
Currently, the US regulatory labeling requirements do not specify how the
strengths are labeled for drugs which are salts. The manufacturer can express the drug
strength as the salt form or as free acid/base. If the manufacturer chooses to express the
strength as the salt form, it is implied that the active moiety content is the labeled strength
multiplied by the weight fraction of the drug in the salt form. For example, the package
insert of metoprolol tartrate [10] states:
Metoprolol tartrate USP, is a selective beta1-adrenoreceptor blocking
agent, available as 50- and 100-mg tablets for oral administration…
Metoprolol tartrate USP is (±)-1-(Isopropylamino)-3-[p-(2methoxyethyl)phenoxy]-2-propanol
L-(+)-tartrate
(2:1)
salt…
Metoprolol tartrate USP is a white, practically odorless, crystalline
powder with a molecular weight of 684.82.
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In this case, the MW of metoprolol (free base) is 267 (not given in the package insert).
The free base weight fraction is calculated to be 78.0%. Therefore, a 100 mg strength
metoprolol tartrate tablet contains only 78 mg metoprolol.
If the manufacturer expresses the strength as the free base/acid form, the
equivalent strength terms are described explicitly in the package insert. Below is an
example from the escitalopram oxalate package insert [10]:
The molecular formula is C20H21FN2O•C2H2O4 and the
molecular weight is 414.40. Lexapro® tablets are film-coated,
round tablets containing escitalopram oxalate in strengths
equivalent to 5 mg, 10 mg, and 20 mg escitalopram base.

Based on the survey data of the top 200 US drugs described in the Results section,
there is no clear trend or consensus among industry regarding the strength labeling for
salts. About 54% of the salt drugs are labeled as salts and the remaining as free
acids/bases. This inconsistent labeling practice can lead to confusion among
pharmaceutical scientists and health care practitioners.
The misinterpretation of the salt vs. free forms can lead to calculation errors,
which can impact many critical activities. For example, the strengths of all escitalopram
oxalate products are expressed as the free base [10]. If a pharmacist uses the escitalopram
oxalate drug substance to compound 15 mg strength capsules, he will need 19 mg
escitalopram oxalate per capsule. However, if the pharmacist misinterprets the strength
expression as the salt, he will use only 15 mg escitalopram oxalate per capsule, and the
final capsule strength will be 21.7% sub-potent. A similar error can occur if an analytical
scientist uses the escitalopram oxalate material to prepare a standard solution without
adjusting the calculations to account for the weight of the oxalate.
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Non-harmonized labeling practice of the salts among industry can also complicate
the strength labeling of new products based on alternative forms or combinations of
existing drugs. Two examples are discussed below.
Metoprolol was first developed and marketed as a tartrate salt. The strengths of
the metoprolol tartrate products (tablets and iv injections) were labeled based on the salt
[10]. The metoprolol succinate salt was later developed as the API form for the extended
release oral tablets. Due to the pre-existing tablet strengths based on the tartrate salt form,
the new metoprolol succinate tablets were labeled based on the tartrate salt to maintain
consistency (see excerpt from package insert [10] below).
Metoprolol succinate extended-release tablets are a beta1selective (cardioselective) adrenoceptor blocking agent, for oral
administration, available as extended release tablets... The
tablets contain 23.75 mg, 47.50 mg, 95 mg and 190 mg of
metoprolol succinate equivalent to 25 mg, 50 mg, 100 mg and
200 mg of metoprolol tartrate USP, respectively.

It is perplexing that the strength of a metoprolol succinate tablet does not reflect the
quantity of metoprolol succinate in the tablet but rather the equivalent quantity of
metoprolol tartrate. In other words, a 25 mg metoprolol succinate tablet contains only
23.75 mg metoprolol succinate which is equivalent to 25 mg metoprolol tartrate. This
confusing situation could have been avoided if the strengths of the original metoprolol
tartrate tablets had been labeled based on the free base.
The second example involves amlodipine besylate and benazepril hydrochloride.
Both drugs were initially marketed as individual oral tablet products. The amlodipine
besylate tablets were labeled based on the free base [10], and the benazepril
hydrochloride tablets were labeled based on the salt [10]. The combination products of
these two drugs were later developed and marketed. Due to the pre-existing single drug
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products, the strengths of the combo capsules were expressed as the free base for
amlodipine besylate and as the salt for benazepril HCl (see excerpt from package insert
[10] below).
Amlodipine besylate and benazepril hydrochloride capsules are
a combination of amlodipine besylate and benazepril
hydrochloride. The capsules are formulated in six different
strengths for oral administration with a combination of
amlodipine besylate equivalent to 2.5 mg, 5 mg or 10 mg of
amlodipine, with 10 mg, 20 mg or 40 mg of benazepril
hydrochloride providing for the following available
combinations: 2.5/10 mg, 5/10 mg, 5/20 mg, 5/40 mg, 10/20 mg
and 10/40 mg.

Based on the issues and examples described above, it should become evident that
a more consistent strength labeling practice should be promoted for pharmaceutical salts
to avoid unnecessary confusion and errors. The authors recommend the approach to
express the strengths of salts based on the free acid/base forms. This approach states the
exact quantity of the active moiety of the drug in the dosage form. It eliminates potential
labeling issues when new forms of the same drug are developed and marketed at a later
date.
It is also worthwhile to emphasize that while this survey focused only on the
marketed drug products, the recommendation above needs to be implemented for clinical
trial materials to achieve the desired outcomes for future marketed products.
Even with a standardized labeling approach, scientists and pharmacists still need
to understand the relationship between salts and their free base/acid forms to perform
calculations accurately for sample/dosage preparations. Therefore, it is important to
provide the necessary training to entry level scientists and pharmacists. In addition, it is
recommended that the manufacturers describe the strengths for both the salt and free
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acid/base forms in the package insert to avoid any potential confusion. For example,
clopidogrel bisulfate (Plavix®) is marketed as 75 and 300 mg strengths tablets. Even
though the strengths are expressed as the free base, the package insert [10] states the
strengths for both the salt and the free base without ambiguity:
Plavix for oral administration is provided as either pink, round,
biconvex, debossed, film-coated tablets containing 97.875 mg of
clopidogrel bisulfate which is the molar equivalent of 75 mg of
clopidogrel base or pink, oblong, debossed film-coated tablets
containing 391.5 mg of clopidogrel bisulfate which is the molar
equivalent of 300 mg of clopidogrel base.

CONCLUSIONS
A survey of the top 200 US drugs revealed the inconsistent practice of strength
expression for drugs which were marketed as salts. The strengths were expressed as the
salt forms for 54% drugs and as the free acid/base forms for the remaining 46% drugs.
Non-harmonized labeling practice can lead to unnecessary confusion among
pharmaceutical scientists and healthcare practitioners. The confusion on drug strengths
and forms can result in potential errors in calculations and dosing, especially when the
drugs are to be compounded extemporaneously prior to use. This inconsistent labeling
practice can also complicate the strength labeling when new products of existing drugs
are developed, such as new salts and combination products. The authors recommend the
FDA and industry to standardize the labeling format for salts and preferably express the
drug strengths based on the free acid/base forms.
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Figure 1. Summary results of top 200 drugs to assess the current industry practice of
drug strength expression for salts.
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Table 1. Drug strength expressions for salts of acidic drugs from the top 200 list.

a.
b.

Rank a

Drug b

Strength Expression As

4

Atorvastatin Calcium

free acid

5

Levothyroxine Sodium

salt form

9

Esomeprazole Magnesium

free acid

10

Montelukast Sodium

free acid

16

Rosuvastatin Calcium

salt form

36

Warfarin Sodium

salt form

48

Amoxicillin Trihydrate/
Potassium Clavulanate

free acid

53

Pravastatin Sodium

salt form

75

Alendronate Sodium

free acid

115

Penicillin V Potassium

free acid

142

Risedronate Sodium

salt form

152

Pantoprazole Sodium

free acid

187

Naproxen

salt form

The ranking information was obtained from Reference 9.
Some API salts were used in several generic or combination products. Only the highest
ranking product was included for each API salt.
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Table 2. Drug strength expressions for salts of basic drugs from the top 200 list.
Rank a

Drug b

Strength Expression As

1

Hydrocodone/APAP

salt form

8

Clopidogrel Bisulfate

free base

11

Metoprolol Tartrate

salt form

13

Escitalopram Oxalate

free base

18

Albuterol Sulfate

free base

19

Metformin HCl

salt form

20

Sertraline HCl

free base

22

Metoprolol Succinate

salt form (as tartrate salt)

24

Zolpidem Tartrate

salt form

25

Fluticasone propionate/
Salmeterol xinafoate

free base

29

Trazodone HCl

salt form

33

Tramadol HCl

salt form

35

Duloxetine Hydrochloride

free base

37

Amlodipine Besylate

free base

42

Quetiapine Fumarate

free base

43

Promethazine HCl

salt form

52

Pioglitazone

free base

56

Fluoxetine HCl

free base

64

Donepazil Hydrochloride

salt form

66

APAP/Codeine

salt form

70

Ciprofloxacin HCl

free base

77

Venlafaxine Hydrochloride

free base

79

Sildenafil Citrate

free base

83

Citalopram Hydrobromide

free base

93

Cyclobenzaprine HCl

salt form

95

Methylphenidate HCl

salt form
16

a.
b.

96

Fexofenadine HCl

salt form

98

Propoxyphene-N/APAP

salt form

104

Memantine Hydrochloride

salt form

118

Sitagliptin Phosphate

free base

120

Amitriptyline Hydrochloride

salt form

121

Clonidine Hydrochloride

salt form

125

Lisdexamfetamine Dimesylate

salt form

128

Oxycodone Hydrochloride

salt form

150

Doxycycline Hyclate

free base

157

Tamsulosin Hydrochloride

salt form

161

Paroxetine Hydrochloride

free base

163

Buprenorphine Hydrochloride /
Naloxone Hydrochloride

free base (both actives)

165

Enalapril Maleate

salt form

174

Benazepril Hydrochloride

salt form

175

Olanzapine Pamoate

free base

179

Tolterodine Tartrate

salt form

183

Amphetamine Salts

salt form

188

Ranitidine Hydrochloride

free base

191

Diltiazem Hydrochloride

salt form

197

Verapamil Hydrochloride SR

salt form

The ranking information was obtained from Reference 9.
Some API salts were used in several generic or combination products. Only the highest ranking
product was included for each API salt.
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